Ana Alves Oliveira

Ana Alves Oliveira

Auto-generated profile, based on publicly available information

Ana Alves Oliveira

Pathology Department, Hospital Garcia de Orta, Av. Torrado da Silva, 2805-267, Almada, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2013 in Pulmonology
Verified
Journal Article
Open access
FVF. Viveiros
F. Viveiros
JGJ. Gomes
J. Gomes
AOA. Oliveira
A. Oliveira
SNSofia Neves
Sofia Neves
JAJ. Almeida
J. Almeida
JSJ. Moura e Sá
J. Moura e Sá
Post-intubation tracheal stenosis (PITS) continues to be challenging in terms of diagnosis, management and prevention. Recurrence is common because of excessive granulation tissue formation and an insidious process of scar contracture. Topical application of mitomycin-C (MMC) as an adjuvant treatment for endoscopic management of stenosis has shown good results. The authors aimed to evaluate the results of MMC topical application following bronchoscopic dilatation as an adjuvant in PITS treatment. Retrospectively selected patients with PITS who had had rigid bronchoscopy (RB) dilatation followed by MMC application as adjuvant to endoscopic treatment. MMC in a concentration of 0.4 mg/ml was applied with a cotton stiletto around the stenotic lesion and granulation tissue for 3 minutes. Eleven patients with PITS, with a median initial tracheal stenosis of 75% of the lumen, underwent RB/MMC treatment. Mean MMC sessions performed/patient was 3.5, with good response and prolonged decrease in granulation tissue formation in 55% of cases, moderate in 18% and relapse in 27%. Mean stenosis improvement was 34%. Topical MMC application at 0.4 mg/ml concentration seems to be associated with good results as adjuvant in PITS management with decrease in granulation tissue and sustained improvement in lumen diameter.

1 August 2018 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AOAna Alves Oliveira
Ana Alves Oliveira
FPFilipa Pedro
Filipa Pedro
NCNuno Craveiro
Nuno Craveiro
ACAna Vera Cruz
Ana Vera Cruz
RARaquel Sousa Almeida
Raquel Sousa Almeida
CSCristina Santos
Cristina Santos
SUMMARY Sodium polystyrene sulfonate (PSP) or Kayexalate is a cation-exchange resin, widely used in the management of hyperkalaemia due to renal disease. A rare, yet potentially dangerous, adverse event related to sodium polystyrene sulfonate use is intestinal mucosal injury, especially in the colon. The injury to the gastrointestinal mucosa can range from mild and superficial to wall necrosis and bowel perforation. The mechanism that leads to mucosal damage remains unclear. However, it is believed that sorbitol, commonly given to counteract PSP’s tendency to cause constipation, may play an important role in the development of gastrointestinal injury. Other potential risk factors are uraemia or end-stage renal disease, hemodynamic instability, solid organ transplantation, postoperative status and concomitant opioid administration. The authors present a case of diarrhoea and haematochezia after the administration of PSP without sorbitol, in a patient with hyperkalaemia due to acute kidney injury, in the absence of other risk factors. A colonoscopy was performed and revealed a rectal ulcer which histological findings were suggestive of mucosal injury due to Kayexalate deposition. This case supports the concept that this widely used drug can itself, without sorbitol, cause injury to the gastrointestinal wall. Even though this is a rare adverse effect, the widespread use of this medication may put a large population at risk.

1 January 2020 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
GSGabriela F. Santos
Gabriela F. Santos
JPJoão Portela
João Portela
DADespoina Argyropoulou
Despoina Argyropoulou
RVRita Varudo
Rita Varudo
IRInes Diegues Rodrigues
Ines Diegues Rodrigues
AFAntero Vale Fernandes
Antero Vale Fernandes
We report a clinical case of a 39-year old male, without any known previous medical condition but with occupational exposure to paints and dust cement, who presented an autoimmune pulmonary alveolar proteinosis (PAP) triggered by exposure to toxic inhalation at his workplace. PAP is a rare lung disease characterized by intra-alveolar abnormal accumulation of surfactant. The presence of a crazy-paving pattern in high-resolution computed tomography scan brings the suspicion of PAP although histopathology results of bronchoalveolar lavage are always required for its final diagnosis. The autoimmune form of PAP due to toxic inhalation, such as the one here described, is rare and it is usually difficult to establish a causal relationship.

1 July 2018 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
FPFilipa Pedro
Filipa Pedro
YAYahia Abuowda
Yahia Abuowda
NCNuno Craveiro
Nuno Craveiro
AOAna Alves Oliveira
Ana Alves Oliveira
AMAna Mestre
Ana Mestre
CSCristina Santos
Cristina Santos
SUMMARY The authors report a case of a 69-year-old man with idiopathic leukocytoclastic cutaneous vasculitis. For three years, the lesions recurred with progressive worsening and were associated with systemic manifestations of low-grade fever, weight loss and raised inflammatory markers. The patient latter presented a 6th cranial nerve involvement, raising the concern of a possible systemic vasculitis, which was latter evidenced by the development of deep vein thrombosis and angina pectoris. The treatment of the patient witch based on the decreasing of inflammatory activity, by using effective immunosuppressive therapy, with lower toxicity is more important than identifying the type of the vasculitis. This case illustrates the importance of awareness for the systemic involvement that can occur in up to 50% of patients with leukocytoclastic cutaneous vasculitis.